首页> 外文期刊>Biological & pharmaceutical bulletin >Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets.
【24h】

Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets.

机译:在多次口服50毫克剂量的辅酶Q10缓释片或常规片后,亚洲男性的总辅酶Q10浓度。

获取原文
获取原文并翻译 | 示例
       

摘要

Coenzyme Q(10) (CoQ(10)), a highly lipophilic compound present in the inner mitochondrial membrane, is essential for production of cellular energy in the form of ATP. CoQ(10) is used as a dietary supplement and for treatment of various cardiovascular disorders. Our goal was to compare the CoQ(10) levels in Asians following multiple oral doses administered as sustained release or regular tablets. Twenty healthy male volunteers (19-23 years old) were divided into two equal groups. Each subject in Group I received 50 mg oral doses of coenzyme Q(10) as sustained release tablets once a day for fifteen days, while subject in Group II received 50 mg doses of coenzyme Q(10) regular tablets. The CoQ(10) levels were measured by HPLC-UV (reverse phase ODS column, 10 microm, 250 x 4.6 mm; oven temperature 30 degrees C). Mobile phase was constituted by methanol-ethanol 9 : 1 v/v. Flow rate was 1.5 ml/min and UV detection was carried out at 275 nm. Coenzyme Q(9) was used as an internal standard. CoQ(10) baseline in the morning was 0.88+/-0.48 mg/l. Following 1 week 50 mg/d dosing of CoQ(10), plasma CoQ(10) concentrations increased to 1.85+/-1.03 mg/l for sustained release tablets and up to 1.37+/-0.74mg/l for regular tablets. The net increment proportion in AUC for sustained release and regular tablets were 148.26+/-176.56%, 102.57+/-130.00%, respectively. Both preparations significantly increased the systemic exposure when compared to endogenous baseline.
机译:辅酶Q(10)(CoQ(10))是线粒体内膜中存在的高度亲脂性化合物,对于产生ATP形式的细胞能量至关重要。辅酶Q(10)用作膳食补充剂并用于治疗各种心血管疾病。我们的目标是比较以持续释放或常规片剂形式多次口服给药后亚洲人的CoQ(10)水平。二十名健康的男性志愿者(19-23岁)被分为两组。第一组的每个受试者每天口服一次,剂量为持续释放片剂的50毫克辅酶Q(10),持续十五天,而第二组的受试者,则接受50毫克剂量的辅酶Q(10)常规片剂。 CoQ(10)水平通过HPLC-UV(反相ODS色谱柱,10微米,250 x 4.6毫米;柱箱温度30摄氏度)测量。流动相由甲醇-乙醇9:1 v / v组成。流速为1.5ml / min,并且在275nm下进行UV检测。辅酶Q(9)用作内标。早晨的CoQ(10)基线为0.88 +/- 0.48 mg / l。服用CoQ(10)50 mg / d 1周后,持续释放片剂的血浆CoQ(10)浓度增加到1.85 +/- 1.03 mg / l,而常规片剂则增加到1.37 +/- 0.74mg / l。持续释放和常规片剂在AUC中的净增量比例分别为148.26 +/- 176.56%,102.57 +/- 130.00%。与内源性基线相比,两种制剂均显着增加了全身暴露。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号